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Introduction {#sec001}
============

Disseminated intravascular coagulation (DIC) is a syndrome characterized by activation of blood coagulation, resulting in intravascular thrombin and fibrin generation, with thrombosis of small- to medium-sized vessels, consequently leading to organ dysfunction and severe bleeding \[[@pone.0205146.ref001]\]. A Japanese study based on a national administrative database reported that 34,711 DIC patients were referred to hospitals between 2010 and 2012 \[[@pone.0205146.ref002]\]. Among those with infectious diseases, the in-hospital mortality within 28 days was 27.7% in 2012 \[[@pone.0205146.ref002]\]. DIC can occur as a complication of infection, sepsis, solid cancers, hematological malignancies, obstetric diseases, trauma, aneurysms, and liver diseases.

DIC results from the interaction of two hemodynamic processes, hypercoagulation and hyperfibrinolysis. When hypercoagulation is predominant, as seen in patients with infection, particularly sepsis, the main sign is organ failure. This type of DIC is referred to as organ failure type, hypercoagulation predominance type, or hypofibrinolysis type. Bleeding is the primary symptom when hyperfibrinolysis is predominant (referred to as bleeding type or hyperfibrinolysis predominance type), as seen in patients with leukemia, obstetric diseases, or aortic aneurysms \[[@pone.0205146.ref003]\].

The prognosis of patients who present with DIC is extremely poor. In a previous report, a high resolution rate from DIC was observed in obstetric diseases and hematologic malignancies, but poor outcomes were observed in trauma/burn victims and those with infectious disease \[[@pone.0205146.ref004]\].

Current international and local treatment guidelines for DIC management \[[@pone.0205146.ref005]--[@pone.0205146.ref009]\] recommend the treatment of the underlying condition in patients with bleeding, organ failure, and non-symptomatic types of DIC. However, blood transfusions are needed in patients with massive bleeding secondary to DIC. Additional treatment aimed at normalizing/stabilizing the coagulation system abnormalities is sometimes required \[[@pone.0205146.ref003], [@pone.0205146.ref010]\]. This includes heparin or an antithrombin (AT-III) derivative, platelet concentrate, fresh frozen plasma, serine protease inhibitor, factor Xa and fibrinogen derivatives (hereafter referred to as "non-recombinant thrombomodulin \[rTM\] treatments"), and rTM.

rTM (Recomodulin^TM^) is composed of the active, extracellular domain of thrombomodulin and binds to thrombin to inactivate coagulation. The thrombin--rTM complex activates protein C to produce activated protein C, which inactivates factors VIIIa and factor Va in the presence of protein S, inhibiting further thrombin formation \[[@pone.0205146.ref011], [@pone.0205146.ref012]\]. rTM suppresses thrombin production at a concentration range that does not inhibit the blood-clotting activity of thrombin.

In a phase III study comparing the efficacy and safety of rTM to those of low-dose heparin for the treatment of DIC in 232 patients with hematologic malignancy or infection, rTM was found to be superior to heparin in terms of bleeding symptoms and DIC resolution \[[@pone.0205146.ref012]\]. Additionally, the incidence rates of bleeding-related adverse events (AEs) were lower with rTM compared with heparin. In terms of safety, rTM is superior to heparin, the current standard DIC therapy \[[@pone.0205146.ref012]\], as rTM does not increase the bleeding risk, despite resulting in sufficient anticoagulation. However, only a few postmarketing studies \[[@pone.0205146.ref013], [@pone.0205146.ref014]\] have investigated the incidence rates of bleeding-related AEs during rTM treatment in a real-world clinical setting.

For the present study, we hypothesized that rTM treatment for DIC after surgery does not increase the incidence of bleeding-related AEs compared with other DIC treatments. Thus, the main objective of this study was to determine whether there was a difference in the incidence of bleeding-related AEs between the rTM group and the group receiving other DIC treatments. For this purpose, we analyzed data from a large population obtained from the medical information database by Medical Data Vision Co., Ltd. (MDV). As surgery could influence the onset of bleeding-related AEs, we also investigated the incidence of such AEs by type of surgery (surgery of the liver, gallbladder, and pancreas; surgery related to other gastrointestinal organs; and surgery related to the heart and cardiovascular systems). Moreover, we investigated the incidence of bleeding-related AEs when blood transfusion or hemostatic procedures were administered to treat DIC. We showed that rTM treatment for Japanese postsurgical patients who develop DIC was associated with significantly fewer bleeding-related AEs compared with those receiving other DIC treatments, which confirmed our hypothesis.

Materials and methods {#sec002}
=====================

Database, study design, setting, and definitions {#sec003}
------------------------------------------------

This was a cohort study using data from 22 centers in Japan obtained from a large medical database collected by MDV. The MDV medical information database is the largest medical information database in Japan, with more than 10 million registered patients (approximately 10% of the Japanese population)--a sample with a similar age distribution to the Japanese population; therefore, the data are considered highly generalizable. The database is based on Diagnosis Procedure Combination data and receipt data provided by acute-phase medical institutions in Japan and covers approximately 15% of all acute-phase medical institutions in Japan, as well as including information on medical treatments, drugs prescribed, and disease scale. As of the end of May 2017, approximately 18,630,000 pediatric and adult patients have been registered in the database.

All participants were Japanese. Participants were divided into two groups for comparison: patients with DIC receiving rTM (the rTM group) and patients with DIC treated with other agents (the non-rTM group). The study registration period was between 1 April 2010 and 31 August 2015.

Patients were considered to be exposed to rTM if the day of the initial administration of rTM was within 1 week after surgery. The initial administration date was defined as the date in which the patient received rTM for the first time. Data of patients who were initially administered rTM within 1 week after surgery were collected using the receipt code from the MDV medical information database. The follow-up period was defined as the time elapsed from the first day of the month when DIC treatment started up to the last day of the next month of surgery. A bleeding-related AE was defined based on the International Classification of Diseases version 10 (ICD-10), and an event was defined as when the diagnosed disease code corresponded to a defined list of bleeding AEs (**[S1 Table](#pone.0205146.s005){ref-type="supplementary-material"}**). Bleeding AEs included mild to severe events, such as bleeding from external and internal (organ) injuries and bleeding that caused inflammation, such as enteritis, hematoma, or purpura associated with bleeding, and blood disorders.

Approval of the study protocol was given by the Institutional Review Board of the Tohoku University Graduate School of Medicine (2017-1-537, approved on 25 September 2017). The need for informed consent was waived as this study analyzed anonymous patient data from a large database. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology guidelines (**[S1 STROBE Checklist](#pone.0205146.s001){ref-type="supplementary-material"}**).

Participants {#sec004}
------------

The target population of this study included patients who presented emergency rooms and who were then admitted to large medical institutions that were part of the database. The inclusion criteria were as follows: Inpatients diagnosed with DIC for the first time according to ICD-10 code D65 (disseminated intravascular coagulation \[defibrination syndrome\]); patients coded to have received DIC treatment with rTM and/or other agents on electronic medical and billing records; and patients coded to have received medical treatment defined as "surgery" on electronic medical and billing records (in this study, patients were classified into four groups as patients who received: 1) all types of surgery \[including the following surgeries\]; 2) hepatic, biliary, or pancreatic surgery; 3) gastrointestinal surgery; and 4) cardiac or cardiovascular surgery).

The exclusion criteria were as follows: Patients lacking a record of outcome data for hospital admission and/or discharge at the time of initial diagnosis of DIC; patients aged less than 18 years; patients with gynecologic/obstetric conditions (women who were pregnant or possibly pregnant); patients who died within 2 days after admission; patients who underwent surgery ≥1 month before the diagnosis of DIC; patients who did not undergo DIC treatment; patients who had received the initial dose of DIC treatment prior to the day of surgery or \>1 week after surgery; patients lacking blood test data (peripheral blood); patients with intracranial hemorrhage, pulmonary hemorrhage, or gastrointestinal hemorrhage (contraindications for rTM treatment as stated in the Japanese product information) before DIC treatment; and patients who had received at least 1 dose of rTM but no initial prescription of rTM on the day of the surgery or within 1 week after surgery.

Primary endpoint {#sec005}
----------------

The primary endpoint of this study was the incidence rate of bleeding-related AEs by type of surgery.

Secondary endpoint {#sec006}
------------------

The secondary endpoint was the incidence rate of bleeding-related AEs based on whether or not blood transfusion or a hemostatic procedure was administered after the day of DIC treatment.

Measurements and variables {#sec007}
--------------------------

Exposure was defined as the initial prescription of rTM or other treatments for DIC on the day of the surgery and within 1 week after surgery. The day of initial prescription was defined as the earliest date at which the patient was prescribed rTM or other non-rTM agents. The baseline characteristics recorded were sex, age, concomitant drugs, concomitant diseases, procedures required during hospitalization, blood or blood product transfusion, and category of the medical institution (based on the number of beds as hospital scale data).

The concomitant drugs allowed were as follows: catecholamine, antibiotics, antifungal drugs, other DIC treatments, steroids, neutrophil elastase inhibitor (sivelestat), and immunoglobulin. The non-rTM treatments allowed were AT-III derivative or heparin, platelet concentrate, fresh frozen plasma, serine protease inhibitor, and factor Xa and fibrinogen derivatives.

Concomitant diseases were defined as target diseases of the Charlson Comorbidity Index and included myocardial infarction, congestive heart failure, peripheral vascular disorder, cerebrovascular disorder, dementia, chronic pulmonary disease, collagen disease, peptic ulcer, mild hepatic disease, diabetes mellitus, hemiplegia, renal dysfunction, solid cancer/leukemia/lymphoma, moderate to severe renal dysfunction, metastatic solid tumor, and AIDS/HIV. Concomitant diseases were defined according to ICD-10 codes used in a previous study \[[@pone.0205146.ref015]\].

Procedures required during hospitalization were defined as ventilator, dialysis, extracorporeal membrane oxygenation, intraaortic balloon pumping, central venous catheterization, pleural effusion drainage, blood purification therapy, and blood test for the coagulation and fibrinolytic system. Blood transfusion was categorized as red blood cell transfusion and whole blood transfusion (irradiated leukocyte-reduced whole blood or leukocyte-reduced whole blood). Laboratory test values for platelet count (\<80,000/mm^3^), creatinine, bilirubin, and fibrinogen/fibrin degradation products (FDP)/D-dimer were collected but not tested for intergroup comparison.

Study size {#sec008}
----------

In a survey of rTM use, it was reported that bleeding-related AEs were observed in 223/4062 patients (5.5%) \[[@pone.0205146.ref016]\]. Under the assumption that the incidence of bleeding-related AEs would be similar to the above in the rTM group and that the incidence of bleeding-related AEs was 6.1% (risk ratio: 0.9), 6.9% (risk ratio: 0.8), and 7.9% (risk ratio: 0.7) in the non-rTM group, the statistical power would be 13.4%, 47.5%, and 87.8%, respectively, for 2150 patients per group.

Statistical analysis {#sec009}
--------------------

Patient background characteristics are presented as n (%), mean ± standard deviation (SD), and median (minimum and maximum). Other variables are presented as risk ratios (point estimations and 95% confidence intervals \[CI\]). The risk ratio was log-transformed, and the Wald test was used to assess the significance of between-group differences. The present analysis was performed on selected patients from the database according to the inclusion and exclusion criteria. Propensity-matched rTM and Non-rTM groups were defined by the propensity score. By using background factors (sex, age, presence/absence of concomitant drugs, presence/absence of concomitant diseases, presence/absence of procedures, presence/absence of blood transfusion, and hospital category based on the number of beds \[hospital scale data\]), the propensity score was calculated using a logistic regression model. No laboratory parameters were used for propensity score calculation. The standard deviation of the logit of the propensity score was calculated.

For propensity score matching, we used the GREEDY algorithm (gmatch.sas available at <http://www.mayo.edu/research/documents/gmatchsas/doc-10027248>). One-to-one pair matching was conducted. rTM administration was set as the standard, and matching was conducted with the patients who were within the range of 0.25-fold of the standard deviation. SAS v 9.4 (SAS Institute, Cary, NC, USA) was used for conducting the statistical analyses.

Results {#sec010}
=======

Participants {#sec011}
------------

**[Fig 1](#pone.0205146.g001){ref-type="fig"}** shows the patient disposition and the number of patients analyzed for propensity score matching and included in the analysis set for each treatment group.

![Flow diagram illustrating patient enrollment (all types of surgery).\
MDV, Medical Datavision; DIC, disseminated intravascular coagulation; rTM, recombinant thrombomodulin; ICH, intracranial hemorrhage.](pone.0205146.g001){#pone.0205146.g001}

Of the 28,163 patients identified in the database, 6918 were included in the cohort after applying the inclusion and exclusion criteria. The propensity score was calculated for 2584 and 4323 patients in each group. After propensity score matching, a total of 4234 patients were included in the main analysis: 2117 patients in the rTM group and 2117 patients in the non-rTM group.

Of the 4323 patients who underwent surgery of any type, 1136 patients underwent hepatic, biliary, or pancreatic surgery; 1228 patients underwent other gastrointestinal surgery; and 878 patients underwent cardiac or cardiovascular surgery. Patient disposition by type of surgery is shown in **[S1](#pone.0205146.s002){ref-type="supplementary-material"}--[S3](#pone.0205146.s004){ref-type="supplementary-material"} Figs**.

Baseline characteristics {#sec012}
------------------------

Patient baseline demographic and clinical characteristics are shown in **[Table 1](#pone.0205146.t001){ref-type="table"}.**

10.1371/journal.pone.0205146.t001

###### Demographic and clinical baseline characteristics.

![](pone.0205146.t001){#pone.0205146.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Item                                                        Classification               Before matching   After matching                                                             
  ----------------------------------------------------------- ---------------------------- ----------------- ---------------- ------------- -------------- -------------- ------------- ------
  Sex, n (%)                                                  Male                                           1350 (52.1)      2589 (59.8)   15.6           1125 (53.1)    1097 (51.8)   2.6

                                                              Female                                         1240 (47.9)      1739 (40.2)   \-             992 (46.9)     1020 (48.2)   \-

  Age, years                                                  n                                              2590             4328          \-             2117           2117          \-

                                                              Median (Minimum/\                              76.0\            74.0\         \-             76.0\          76.0\         \-
                                                              maximum)                                       (18/102)         (18/103)                     (18/102)       (19/103)      

  Concomitant drugs, n (%)                                    Catecholamine                No                981 (37.9)       1840 (42.5)   9.5            886 (41.9)     912 (43.1)    2.5

  Yes                                                         1609 (62.1)                  2488 (57.5)       \-               1231 (58.1)   1205 (56.9)    \-                           

  Antibiotics                                                 No                           62 (2.4)          267 (6.2)        18.7          60 (2.8)       53 (2.5)       2.1           

  Yes                                                         2528 (97.6)                  4061 (93.8)       \-               2057 (97.2)   2064 (97.5)    \-                           

  Antifungals                                                 No                           2462 (95.1)       4252 (98.2)      17.8          2041 (96.4)    2051 (96.9)    2.6           

  Yes                                                         128 (4.9)                    76 (1.8)          \-               76 (3.6)      66 (3.1)       \-                           

  Other drugs for DIC treatment                               No                           737(28.5)         0(0.0)           89.2          690 (32.6)     0 (0.0)        98.3          

  Yes                                                         1853 (71.5)                  4328 (100.0)      \-               1427 (67.4)   2117(100.0)    \-                           

  Steroids                                                    No                           1969 (76.0)       3285 (75.9)      0.3           1647 (77.8)    1676 (79.2)    3.3           

  Yes                                                         621 (24.0)                   1043 (24.1)       \-               470 (22.2)    441 (20.8)     \-                           

  Neutrophil elastase inhibitors (Sivelestat)                 No                           2208 (85.3)       3975 (91.8)      20.8          1883 (88.9)    1884 (89.0)    0.2           

  Yes                                                         382 (14.7)                   353(8.2)          \-               234 (11.1)    233 (11.0)     \-                           

  Immunoglobulins                                             No                           1787 (69.0)       3765 (87.0)      44.5          1603 (75.7)    1624 (76.7)    2.3           

  Yes                                                         803 (31.0)                   563 (13.0)        \-               514 (24.3)    493 (23.3)     \-                           

  Complications, n (%)                                        Myocardial infarction        No                2532 (97.8)      4121 (95.2)   13.9           2063 (97.4)    2065 (97.5)   0.6

  Yes                                                         58 (2.2)                     207 (4.8)         \-               54 (2.6)      52 (2.5)       \-                           

  Congestive heart failure                                    No                           2326 (89.8)       3631 (83.9)      17.6          1890 (89.3)    1886 (89.1)    0.6           

  Yes                                                         264 (10.2)                   697 (16.1)        \-               227 (10.7)    231 (10.9)     \-                           

  Peripheral vascular disease                                 No                           2513 (97.0)       3993 (92.3)      21.3          2049 (96.8)    2047 (96.7)    0.5           

  Yes                                                         77 (3.0)                     335 (7.7)         \-               68 (3.2)      70 (3.3)       \-                           

  Cerebral vascular disease                                   No                           2432 (93.9)       4024 (93.0)      3.7           1980 (93.5)    1973 (93.2)    1.3           

  Yes                                                         158 (6.1)                    304 (7.0)         \-               137 (6.5)     144 (6.8)      \-                           

  Dementia                                                    No                           2526 (97.5)       4260 (98.4)      6.4           2064 (97.5)    2064 (97.5)    0.0           

  Yes                                                         64 (2.5)                     68 (1.6)          \-               53 (2.5)      53 (2.5)       \-                           

  Chronic lung disease                                        No                           2508 (96.8)       4144 (95.7)      5.7           2042 (96.5)    2046 (96.6)    1.0           

  Yes                                                         82 (3.2)                     184 (4.3)         \-               75 (3.5)      71 (3.4)       \-                           

  Collagen disease                                            No                           2558 (98.8)       4271 (98.7)      0.7           2090 (98.7)    2086 (98.5)    1.6           

  Yes                                                         32 (1.2)                     57 (1.3)          \-               27 (1.3)      31 (1.5)       \-                           

  Peptic ulcer                                                No                           2385 (92.1)       3920 (90.6)      5.4           1938 (91.5)    1954 (92.3)    2.8           

  Yes                                                         205 (7.9)                    408 (9.4)         \-               179 (8.5)     163 (7.7)      \-                           

  Mild liver disease[^a^](#t001fn002){ref-type="table-fn"}    No                           2448 (94.5)       3856 (89.1)      19.9          1988 (93.9)    2007 (94.8)    3.9           

  Yes                                                         142 (5.5)                    472 (10.9)        \-               129 (6.1)     110 (5.2)      \-                           

  Diabetes                                                    No                           2264 (87.4)       3693 (85.3)      6.1           1830 (86.4)    1833 (86.6)    0.4           

  Yes                                                         326 (12.6)                   635 (14.7)        \-               287 (13.6)    284 (13.4)     \-                           

  Hemiplegia                                                  No                           2583 (99.7)       4315 (99.7)      0.6           2111 (99.7)    2113 (99.8)    1.9           

  Yes                                                         7 (0.3)                      13(0.3)           \-               6 (0.3)       4 (0.2)        \-                           

  Renal dysfunction                                           No                           2403 (92.8)       4074 (94.1)      5.5           1981 (93.6)    1982 (93.6)    0.2           

  Yes                                                         187 (7.2)                    254 (5.9)         \-               136 (6.4)     135 (6.4)      \-                           

  Diabetes mellitus with chronic complications                No                           2514 (97.1)       4211 (97.3)      1.4           2057 (97.2)    2059 (97.3)    0.6           

  Yes                                                         76 (2.9)                     117 (2.7)         \-               60 (2.8)      58 (2.7)       \-                           

  Solid cancer, leukemia, lymphoma                            No                           2099 (81.0)       3268 (75.5)      13.5          1672 (79.0)    1700 (80.3)    3.3           

  Yes                                                         491 (19.0)                   1060 (24.5)       \-               445 (21.0)    417 (19.7)     \-                           

  Moderate to high liver dysfunction                          No                           2555 (98.6)       4195 (96.9)      11.7          2083 (98.4)    2091 (98.8)    3.2           

  Yes                                                         35(1.4)                      133 (3.1)         \-               34 (1.6)      26 (1.2)       \-                           

  Metastatic solid tumors                                     No                           2445 (94.4)       3997 (92.4)      8.2           1987 (93.9)    1993 (94.1)    1.2           

  Yes                                                         145 (5.6)                    331 (7.6)         \-               130 (6.1)     124 (5.9)      \-                           

  AIDS/HIV                                                    No                           2588 (99.9)       4327 (100.0)     2.4           2116 (100.0)   2117 (100.0)   3.1           

  Yes                                                         2 (0.1)                      1 (0.0)           \-               1 (0.0)       0 (0.0)        \-                           

  Treatments, n (%)                                           Ventilators                  No                1831 (70.7)      3710 (85.7)   37.0           1675 (79.1)    1705 (80.5)   3.5

  Yes                                                         759 (29.3)                   618 (14.3)        \-               442 (20.9)    412 (19.5)     \-                           

  Dialysis                                                    No                           2157 (83.3)       4047 (93.5)      32.3          1891 (89.3)    1901 (89.8)    1.5           

  Yes                                                         433 (16.7)                   281 (6.5)         \-               226 (10.7)    216 (10.2)     \-                           

  Extracorporeal membrane oxygenation                         No                           2581 (99.7)       4054 (93.7)      33.8          2108 (99.6)    2112 (99.8)    3.3           

  Yes                                                         9 (0.3)                      274 (6.3)         \-               9 (0.4)       5 (0.2)        \-                           

  Intra-aortic balloon pumping                                No                           2555 (98.6)       4232 (97.8)      6.6           2083 (98.4)    2091 (98.8)    3.2           

  Yes                                                         35 (1.4)                     96 (2.2)          \-               34 (1.6)      26 (1.2)       \-                           

  Central venous catheterization                              No                           2578 (99.5)       4298 (99.3)      3.0           2105 (99.4)    2107 (99.5)    1.3           

  Yes                                                         12 (0.5)                     30 (0.7)          \-               12 (0.6)      10 (0.5)       \-                           

  Pleural effusion                                            No                           1681 (64.9)       3766 (87.0)      53.6          1586 (74.9)    1635 (77.2)    5.4           

  Yes                                                         909 (35.1)                   562 (13.0)        \-               531 (25.1)    482 (22.8)     \-                           

  Blood purification therapy                                  No                           2157 (83.3)       4047 (93.5)      32.3          1891 (89.3)    1901 (89.8)    1.5           

  Yes                                                         433 (16.7)                   281 (6.5)         \-               226 (10.7)    216 (10.2)     \-                           

  Coagulation blood test                                      No                           89 (3.4)          623 (14.4)       39.2          88 (4.2)       71 (3.4)       4.2           

  Yes                                                         2501 (96.6)                  3705 (85.6)       \-               2029 (95.8)   2046 (96.6)    \-                           

  Transfusion, n (%)                                          Red blood cell transfusion   No                1852 (71.5)      2748 (63.5)   17.2           1550 (73.2)    1563 (73.8)   1.4

  Yes                                                         738 (28.5)                   1580 (36.5)       \-               567 (26.8)    554 (26.2)     \-                           

  Whole blood transfusion                                     No                           2590 (100.0)      4328 (100.0)     \-            2117 (100.0)   2117 (100.0)   \-            

  Yes                                                         0 (0.0)                      0 (0.0)           \-               0 (0.0)       0 (0.0)        \-                           

  Number of beds in medical facilities, n (%)                 \<200 beds                                     53 (2.0)         222 (5.1)     16.6           44 (2.1)       97 (4.6)      14.0

  ≥200, \<500                                                                              1492 (57.6)       2246 (51.9)      11.5          1237 (58.4)    1138 (53.8)    9.4           

  ≥500                                                                                     1045 (40.3)       1860 (43.0)      5.3           836 (39.5)     882 (41.7)     4.4           

  Platelets (average[^b^](#t001fn003){ref-type="table-fn"})   n                                              175              203           \-             141            96            \-

  Median                                                                                   12.20             14.70            \-            12.10          12.10          \-            

  Creatinine\                                                 n                                              174              203           \-             140            96            \-
  (average[^b^](#t001fn003){ref-type="table-fn"})                                                                                                                                       

  Median                                                                                   1.060             0.850            \-            1.065          0.825          \-            

  Total bilirubin\                                            n                                              163              197           \-             129            95            \-
  (average[^b^](#t001fn003){ref-type="table-fn"})                                                                                                                                       

  Median                                                                                   0.840             0.800            \-            0.840          0.810          \-            

  Direct bilirubin\                                           n                                              92               110           \-             73             56            \-
  (average[^b^](#t001fn003){ref-type="table-fn"})                                                                                                                                       

  Median                                                                                   0.310             0.375            \-            0.300          0.500          \-            

  FDP/D-dimer\                                                n                                              60               56            \-             43             26            \-
  (average[^b^](#t001fn003){ref-type="table-fn"})                                                                                                                                       

  Median                                                                                   8.717             8.150            \-            8.833          7.600          \-            

  Platelets (minimum[^c^](#t001fn004){ref-type="table-fn"})   n                                              175              203           \-             141            96            \-

  Median                                                                                   11.80             14.30            \-            11.80          11.90          \-            

  Creatinine\                                                 n                                              174              203           \-             140            96            \-
  (minimum[^c^](#t001fn004){ref-type="table-fn"})                                                                                                                                       

  Median                                                                                   1.025             0.850            \-            1.030          0.825          \-            

  Total bilirubin\                                            n                                              163              197           \-             129            95            \-
  (minimum[^c^](#t001fn004){ref-type="table-fn"})                                                                                                                                       

  Median                                                                                   0.800             0.800            \-            0.800          0.810          \-            

  Direct bilirubin\                                           n                                              92               110           \-             73             56            \-
  (minimum[^c^](#t001fn004){ref-type="table-fn"})                                                                                                                                       

  Median                                                                                   0.310             0.375            \-            0.300          0.500          \-            

  FDP/D-dimer\                                                n                                              60               56            \-             43             26            \-
  (minimum[^c^](#t001fn004){ref-type="table-fn"})                                                                                                                                       

  Median                                                                                   8.550             8.150            \-            8.600          7.600          \-            

  Platelets\                                                  n                                              175              203                          141            96            
  (maximum[^d^](#t001fn005){ref-type="table-fn"})                                                                                                                                       

  Median                                                                                   12.30             15.00            \-            12.10          12.10          \-            

  Creatinine\                                                 n                                              174              203           \-             140            96            \-
  (maximum[^d^](#t001fn005){ref-type="table-fn"})                                                                                                                                       

  Median                                                                                   1.065             0.850            \-            1.075          0.825          \-            

  Total bilirubin\                                            n                                              163              197           \-             129            95            \-
  (maximum[^d^](#t001fn005){ref-type="table-fn"})                                                                                                                                       

  Median                                                                                   0.870             0.800            \-            0.840          0.810          \-            

  Direct bilirubin\                                           n                                              92               110           \-             73             56            \-
  (maximum[^d^](#t001fn005){ref-type="table-fn"})                                                                                                                                       

  Median                                                                                   0.310             0.375            \-            0.300          0.500          \-            

  FDP/D-dimer\                                                n                                              60               56            \-             43             26            \-
  (maximum[^d^](#t001fn005){ref-type="table-fn"})                                                                                                                                       

  Median                                                                                   8.800             8.150            \-            9.000          7.600          \-            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

rTM, recombinant thrombomodulin; DIC, disseminated intravascular coagulation; FDP, fibrinogen/fibrin degradation products. The total number of patients in each group (2,590 and 4,328 in the rTM and non-rTM group, respectively) shown in [Table 1](#pone.0205146.t001){ref-type="table"}.

^a^Includes severe liver disease (e.g., liver cirrhosis) as defined in a previous study \[[@pone.0205146.ref014]\].

^b^When there were repeated test results, we adopted the average.

^c^When there were repeated test results, we adopted the minimum.

^d^When there were repeated test results, we adopted the maximum.

The mean (± SD) age was 74.1 ± 12.8 years in the rTM group and 72.3 ± 13.2 years in the non-rTM group before matching (standardized difference = 13.6%), and 73.8 ± 13.0 years in the rTM group and 74.1 ± 13.0 years in the non-rTM group (standardized difference = 2.5%) after matching. Of the enrolled patients, 52.1% (n = 1350) in the rTM group and 59.8% (n = 2589) in the non-rTM group were males before matching. After matching, the proportion of male patients was 53.1% (n = 1125) and 51.8% (n = 1097) in the rTM and non-rTM groups, respectively. The usage ratio of non-rTM treatments is shown in **[S2 Table](#pone.0205146.s006){ref-type="supplementary-material"}**.

The standardized difference changes before and after matching in [Table 1](#pone.0205146.t001){ref-type="table"} showed that bias was adjusted. Patient baseline demographic and clinical characteristics by type of surgery before and after propensity score matching are shown in the **[S3](#pone.0205146.s007){ref-type="supplementary-material"}--[S5](#pone.0205146.s009){ref-type="supplementary-material"} Tables**.

Regarding the propensity score, the logistic model was a poor fit for the observed data, based on the significant Hosmer--Lemeshow test result (χ^2^ = 32.6536, flexibility = 8, *p* \< 0.0001). The ability of the propensity score to control for confounding was evaluated by the c-statistic (area under the receiver operating characteristic curve, 0.81), which showed moderate accuracy (any surgery \[0.796\], hepatic, biliary or pancreatic surgery \[0.765\]; other gastrointestinal surgery \[0.796\]; and cardiac and cardiovascular surgery \[0.811\]).

Primary endpoints {#sec013}
-----------------

The incidence rate of bleeding-related AEs was 18.8% (n = 398) during any type of surgery in the rTM group and 24.8% in the non-rTM group (n = 526) (**[Table 2](#pone.0205146.t002){ref-type="table"}**). Overall, the incidence of total bleeding-related AEs was significantly lower (p \<0.001) in the rTM group compared with that in the non-rTM group (risk ratio 0.757, 95% CI 0.674--0.849).

10.1371/journal.pone.0205146.t002

###### Bleeding-related adverse events with an incidence \>1% in patients undergoing any type of surgery.

![](pone.0205146.t002){#pone.0205146.t002g}

  -----------------------------------------------------------------------------------------------------------------
  Bleeding-related adverse events       Groups\                Incidence (%)   Risk ratio                  
                                        (n = 2117 per group)                                               
  ------------------------------------- ---------------------- --------------- ------------ -------------- --------
  All bleeding-related adverse events   non-rTM group          526 (24.8)      1.000        \-             0.0000

                                        rTM group              398 (18.8)      0.757        0.674--0.849   

      Intracranial hemorrhage           non-rTM group          28 (1.3)        1.000        \-             0.0084

                                        rTM group              11 (0.5)        0.393        0.196--0.787   

      Gastrointestinal hemorrhage       non-rTM group          49 (2.3)        1.000        \-             0.1561

                                        rTM group              36 (1.7)        0.735        0.480--1.125   

      Wound hemorrhage                  non-rTM group          23 (1.1)        1.000        \-             0.1958

                                        rTM group              15 (0.7)        0.652        0.341--1.246   

      Other hemorrhage                  non-rTM group          453 (21.4)      1.000        \-             0.0000

                                        rTM group              335 (15.8)      0.740        0.651--0.840   

          Hemorrhagic shock             non-rTM group          251 (11.9)      1.000        \-             0.0000

                                        rTM group              150 (7.1)       0.598        0.493--0.725   

          Hemorrhagic anemia            non-rTM group          140 (6.6)       1.000        \-             0.1070

                                        rTM group              115 (5.4)       0.821        0.647--1.043   

          Postoperative anemia          non-rTM group          32 (1.5)        1.000        \-             0.8990

                                        rTM group              31 (1.5)        0.969        0.593--1.582   

          Acute blood loss anemia       non-rTM group          22 (1.0)        1.000        \-             0.7669

                                        rTM group              24 (1.1)        1.091        0.614--1.939   

          Hemorrhagic trend             non-rTM group          26 (1.2)        1.000        \-             0.0100

                                        rTM group              10 (0.5)        0.385        0.186--0.796   
  -----------------------------------------------------------------------------------------------------------------

rTM, recombinant thrombomodulin; CI, confidence interval

The incidence of total bleeding-related AEs was significantly lower in the rTM group compared with that in the non-rTM group for intracranial hemorrhage (p = 0.0084), other hemorrhages (p \<0.001), hemorrhagic shock (p \<0.001), and hemorrhagic trend (p = 0.010).

Of note, overall, the incidence of anemia caused by acute blood loss was numerically higher in the rTM group (1.1%) compared with that in the non-rTM group (1.0%).

By surgery type, the incidence rate of bleeding-related AEs for hepatic, biliary, or pancreatic surgery was 13.0% (n = 74) in the rTM group and 15.8% (n = 90) in the non-rTM group (risk ratio 0.822, 95% CI 0.618--1.093), the incidence rate for other gastrointestinal surgery (except for hepatic, biliary, or pancreatic surgery) was 31.3% (n = 192) in the rTM group and 31.9% (n = 196) in the non-rTM group (risk ratio 0.98, 95% CI 0.831--1.155); and the incidence rate for cardiac and cardiovascular surgery was 21.4% (n = 94) in the rTM group and 32.3% (n = 142) in the non-rTM group (risk ratio 0.662, 95% CI 0.529--0.829) (**[S6](#pone.0205146.s010){ref-type="supplementary-material"}--[S8](#pone.0205146.s012){ref-type="supplementary-material"} Tables**).

The incidence rate of bleeding-related AEs was significantly lower (p = 0.0003) for cardiac and cardiovascular surgery in the rTM group compared with the non-rTM group. Among other hemorrhages, the incidence rates of hemorrhagic shock (p = 0.0049), anemia caused by acute blood loss (p = 0.0260), and acute massive hemorrhage (p = 0.0535) were significantly lower in the rTM group compared with the non-rTM group. For patients undergoing hepatic, biliary, or pancreatic surgery, the incidence rate of hemorrhagic shock was significantly lower (p = 0.0153) in the rTM group compared with the non-rTM group. There were no significant differences in the incidence rates of bleeding-related AEs among patients undergoing other gastrointestinal surgeries. Among those undergoing hepatic, biliary, or pancreatic surgery or other gastrointestinal surgeries, patients had higher incidences of anemia caused by acute blood loss in the rTM group, although these differences did not reach statistical significance.

Secondary endpoint {#sec014}
------------------

A summary of all bleeding-related AEs with an incidence \>1% in all patients (any type of surgery) and in those undergoing hepatic, biliary, or pancreatic surgery; gastrointestinal surgeries; and cardiac or cardiovascular surgery requiring blood transfusion or a hemostatic procedure after the day of DIC treatment is shown in **[Table 3](#pone.0205146.t003){ref-type="table"}**. The incidence of all bleeding-related AEs in the rTM group (15.0% \[n = 317\]) was significantly lower (p = 0.0001) compared with that (19.5% \[n = 412\]) in the non-rTM group in all patients requiring blood transfusion or a hemostatic procedure after the day of DIC treatment. The only significant difference between the rTM and non-rTM groups regarding the incidence of bleeding-related AEs was noted among patients undergoing cardiac or cardiovascular surgery. The incidence of all bleeding-related AEs was significantly lower among patients undergoing cardiac or cardiovascular surgery treated with rTM (18.5% \[n = 81\]) compared with patients treated with non-rTM drugs (30.1% \[n = 132\]). Similarly, significant differences in favor of rTM treatment were observed for hemorrhagic shock (p = 0.0024), anemia caused by acute blood loss (p = 0.0260), and acute massive hemorrhage (p = 0.0535).

10.1371/journal.pone.0205146.t003

###### Summary of bleeding-related adverse events with an incidence \>1% in all patients and in those undergoing any type of surgery, hepatic, biliary, or pancreatic surgery; gastrointestinal surgeries; and cardiac or cardiovascular surgery requiring blood transfusion or a hemostatic procedure after the day of DIC treatment.

![](pone.0205146.t003){#pone.0205146.t003g}

  All bleeding-related adverse events                                                                  Groups          Patients (n)   Incidence (%)   Risk ratio          
  ---------------------------------------------------------------------------------------------------- --------------- -------------- --------------- -------------- ---- --------
  All bleeding-related adverse events in patients undergoing any type of surgery                       non-rTM group   2117           412 (19.5)      1.000          \-   0.0001
  rTM group                                                                                                            317 (15.0)     0.769           0.673--0.879        
  All bleeding-related adverse events in patients undergoing hepatic, biliary, or pancreatic surgery   non-rTM group   568            66 (11.6)       1.000          \-   0.4470
  rTM group                                                                                                            58 (10.2)      0.879           0.630--1.226        
  All bleeding-related adverse events in patients undergoing gastrointestinal surgeries                non-rTM group   614            156 (25.4)      1.000          \-   0.6439
  rTM group                                                                                                            149 (24.3)     0.955           0.786--1.160        
  All bleeding-related adverse events in patients undergoing cardiac or cardiovascular surgery         non-rTM group   439            132 (30.1)      1.000          \-   0.0001
  rTM group                                                                                                            81 (18.5)      0.614           0.481--0.782        

DIC, disseminated intravascular coagulation; rTM, recombinant thrombomodulin; CI, confidence interval

Results of bleeding-related AEs with an incidence \>1% in patients requiring blood transfusion or a hemostatic procedure after the day of DIC treatment in the rTM/non-rTM groups by surgery type are shown in **[S9](#pone.0205146.s013){ref-type="supplementary-material"}--[S12](#pone.0205146.s016){ref-type="supplementary-material"} Tables**. Significant differences in favor of rTM treatment were observed for intracranial hemorrhage (p = 0.0070) and other hemorrhage (p = 0.0003) (**[S9 Table](#pone.0205146.s013){ref-type="supplementary-material"}**). Among other hemorrhages, significant differences in favor of rTM treatment were observed for hemorrhagic shock (p = 0.0001), hemorrhagic anemia (p = 0.0261), and hemorrhagic trend (p = 0.0198). Among all bleeding-related AEs, hemorrhagic shock had the highest incidence in both non-rTM (8.5%) and rTM groups (5.5%).

Discussion {#sec015}
==========

This study aimed to determine if there was a difference in the incidence of bleeding-related AEs between surgical patients treated with rTM and those receiving other DIC treatments. Thus, we conducted this analysis using data from a large population collected and recorded in a large medical information database. We addressed potential sources of bias in the inclusion and exclusion criteria, definitions of exposure and outcomes, and patient background variables used for the propensity score calculation by referring to previous studies when developing the study protocol \[[@pone.0205146.ref017], [@pone.0205146.ref018]\]. Additionally, the duration of the observation period included evaluations of patients 1 month after the occurrence of the bleeding-related AE. As surgery could influence the onset of bleeding-related AEs, we also investigated the incidence of these by type of surgery (surgery of the liver, gallbladder, and pancreas; surgery related to other gastrointestinal organs; and surgery related to the heart and cardiovascular system). Moreover, we investigated the incidence of bleeding-related AEs when blood transfusion or hemostatic procedure was administered to treat DIC.

In this study, we found a gap in the incidence rate of bleeding-related AEs; the incidence of bleeding-related AEs as found in this study was 15.0% in rTM groups (**[Table 3](#pone.0205146.t003){ref-type="table"}**), while the estimated incidence of bleeding-related AEs according to the product information was 5.5% in the planning stage of this study. This estimated number of 5.5% was the result of a previous surveillance report under actual clinical conditions in Japan. Due to the characteristics of the MDV database, patients in this study were treated at large hospitals. Conversely, in our study, patients from small-scale hospitals were included in the data for the estimated incidence of bleeding-related AEs. Thus, it is possible that patients with a high risk of bleeding were among the patients in our study. As this was a database study and the sample size was limited beforehand, the power was calculated for the primary analyses. As a result, in the primary analysis, the estimated risk ratio was between 0.7 and 0.8 and the power was considered to be retained.

In this study, the incidence rate of total bleeding-related AEs for any surgery was significantly lower in the rTM group compared with that in the non-rTM group. Similar results were obtained for the three types of surgery evaluated (hepatic, biliary, or pancreatic surgery; other gastrointestinal surgery; and cardiac and cardiovascular surgery) requiring blood transfusion or hemostatic procedure the day after DIC treatment. Anemia caused by acute blood loss was more common in the rTM group overall and among those undergoing hepatic, biliary, or pancreatic surgery or other gastrointestinal surgeries, so special attention to this event is necessary. However, there were very few events; thus, the estimated values are not robust.

The most frequently reported bleeding events post-surgery occurred after cardiac surgery (47.4%), non-cardiac thoracic surgery (34.3%), and vascular surgery (31.5%) \[[@pone.0205146.ref019]\]. Our study results indicate that among all bleeding-related AEs, hemorrhagic shock occurred more frequently in both non-rTM and rTM groups. This finding is in accord with the particular impact of cardiac and cardiovascular surgery. By conducting further analyses of our data, it was possible to reveal differences in bleeding-related AEs by surgery type.

The findings of the present study support our hypothesis that rTM treatment for patients diagnosed with DIC after surgery does not increase the incidence of bleeding-related AEs compared with other DIC treatments. This is clinically relevant as it suggests that rTM treatment is a suitable and safe drug among the existing anticoagulants for DIC treatment. It is important to select the appropriate drug to treat DIC, as it is difficult to achieve sufficient anticoagulation in DIC without triggering bleeding events. Nevertheless, anticoagulation is still necessary in DIC given the state of hypercoagulability \[[@pone.0205146.ref003]\].

In a previous medical database study on rTM administration in patients with DIC \[[@pone.0205146.ref017]\], Tagami et al. compared the death rates between the rTM group and the control group in patients with severe pneumonia complicated with sepsis-related DIC and reported that there was no significant difference between groups. The study by Tagami et al., however, differed from our study in that their patients had a more severe type of DIC (i.e., sepsis-related DIC), which may explain the difference in results. Murata et al. \[[@pone.0205146.ref018]\] conducted an observational study comparing the in-hospital mortality, length of hospitalization, and medical costs between the rTM group and the AT-III group in inpatients with DIC associated with infectious diseases. In that study, there was no significant difference in in-hospital mortality between treatment groups; however, the use of rTM was associated with a significant decrease in the length of hospitalization and medical cost in the rTM group compared with the AT-III group. Although this study differed from ours in terms of study design, comparator, and type of DIC that patients presented, there were significant differences in terms of beneficial effects achieved by those treated with rTM compared to AT-III.

This study had several limitations. Because of the characteristics of the MDV database, we could only obtain monthly disease course data, making it difficult to assess the context of surgery during the month of DIC onset or DIC onset with the medical management administered. We were not able to collect reliable data on death as only data on death at the time of discharge were collectable. Additionally, we could only obtain some laboratory test result data (such as platelet count, creatinine, bilirubin, and FDP/D-dimer) in approximately 10% of patients, and thus, we could not consider these factors for matching using propensity scores. However, we did consider concomitant medication for complications related to DIC as a confounding factor. We could not capture information that was not included in the MDV database. For example, we could not differentiate between centers that do and those that do not have emergency departments. Thus, except for the level of care of the centers (i.e., number of beds), detailed information of the centers in which the patients were treated could not be obtained. We acknowledge that the center at which the patient was treated can influence the diagnosis of bleeding, as the examinations, surgical procedures, and indication and administration of blood transfusions, among other factors, tend to differ across centers. Finally, the results of this study cannot be generalized beyond postsurgical Japanese patients who present with DIC.

The results of this cohort study based on data from a large population obtained from the MDV database indicate that rTM treatment for Japanese postsurgical patients who develop DIC was associated with significantly less bleeding-related AEs compared with those receiving other DIC treatments. Our findings may be relevant for clinicians when selecting the most appropriate DIC treatment. In addition to addressing the limitations of the database study design, future research will focus on collecting further data to improve our understanding of the relationship between rTM treatment and bleeding-related AEs in this patient population.
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